Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infection

Part of Human Metapneumovirus Infection

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Respiratory Syncytial Virus Infection

89 trials tracked for Respiratory Syncytial Virus Infection: 31 in phase 3 or 4 and 19 with published results. The most-cited published study has 421 citations.

89Trials tracked
31Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 1 Phase 3 30 Phase 2 29 Phase 1 16 Other / NA 13
  1. Phase 3 A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization Completed · 421 cited
  2. Phase 3 A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children Completed · 181 cited
  3. Phase 3 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Completed · 153 cited
  4. Phase 3 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) Completed · 73 cited
  5. Phase 3 Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above Completed · 50 cited
  6. Phase 3 Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age Completed · 43 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Completed · 38 cited
  2. Phase 3 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above Completed · 36 cited
  3. Phase 3 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age Completed · 24 cited
  4. Phase 3 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease Completed · 21 cited
  5. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above Completed · 18 cited
  6. Phase 3 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above Completed · 14 cited
  7. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above Completed · 10 cited
  8. Phase 3 A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women. Completed · 5 cited
  9. Phase 3 A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above Completed · 4 cited
  10. Phase 3 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above Completed · 1 cited
  11. Phase 3 A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. Completed
  12. Phase 3 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults Completed
  13. Phase 3 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Completed
  14. Phase 4 Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Completed
  15. Phase 3 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed
  16. Phase 3 A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age Completed
  17. Phase 3 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults Completed
  18. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above Completed
  19. Phase 3 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea Completed
  20. Phase 3 A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control Completed
  21. Phase 3 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab Completed
  22. Phase 3 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older Completed
  23. Phase 3 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed
  24. Phase 3 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed
  25. Phase 3 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children Completed
  26. Phase 2 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season Completed
  27. Phase 2 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Completed
  28. Phase 2 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants Completed
  29. Phase 2 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus Completed
  30. Phase 2 Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers Completed
  31. Phase 2 Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants Completed
  32. Phase 2 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed
  33. Phase 2 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects Completed
  34. Phase 2 Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed
  35. Phase 2 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children Completed
  36. Phase 2 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection Completed
  37. Phase 2 Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study Completed
  38. Phase 2 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. Completed
  39. Phase 2 Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) Completed
  40. Phase 2 Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Completed
  41. Phase 2 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults Completed
  42. Phase 2 A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults Completed
  43. Phase 2 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age Completed
  44. Phase 2 Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of antibody-based strategies against RSV and SARS-CoV-2 in infants
Cardiology Sys. Review
Review of antibody-based strategies against RSV and SARS-CoV-2 in infants New antibody treatments for babies lower virus hospitalization risk greatly
This narrative review examines antibody-based strategies against respiratory syncytial virus and SARS-CoV-2 in infants. It reports that nirs…
A review of antibody treatments for babies shows they greatly lower hospitalization risk from respiratory viruses. These medicines stay effe…
Frontiers May 2, 2026
Narrative review on pediatric RSV co-infections and post-pandemic rebound
Pediatrics Sys. Review
Narrative review on pediatric RSV co-infections and post-pandemic rebound RSV Hits Kids Harder When Another Bug Joins In
This narrative review synthesizes evidence on pediatric RSV co-infections in a global context.
It started with a sniffle. Then a cough. By day three, 7-month-old Mia was breathing fast, ribs pulling in with each breath.
Frontiers Apr 24, 2026
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort
Geriatrics & Aging Cohort
Infection status associated with hypoxemia and death rates varying by virus type in a large US cohort Triple Virus Infections Rarer Than Feared — Here’s the Real Risk
This cohort study of 835,987 triple-tested patients in the US Veterans Health Administration examined associations between infection status …
It’s winter. Your throat is scratchy. Your chest feels tight.
Frontiers Apr 23, 2026
Adjuvanted RSV vaccine shows efficacy against RSV disease in older adults with comorbidities
Infectious Disease RCT
Adjuvanted RSV vaccine shows efficacy against RSV disease in older adults with comorbidities One RSV Shot Protects High-Risk Older Adults for Three Full Seasons
This post-hoc analysis of a phase 3 trial evaluated an adjuvanted RSVPreF3 dose in medically stable adults aged 60 and older with underlying…
One RSV shot cuts illness risk by 63% to 75% for older adults with COPD, asthma, diabetes, or obesity over three full seasons.
medRxiv Apr 18, 2026
Methodological review assesses phenotypes for classifying respiratory viruses in English health data
Infectious Disease
Methodological review assesses phenotypes for classifying respiratory viruses in English health data How Doctors Track RSV, Flu, and COVID When Tests Aren't Always Done
This methodological review evaluates phenotypes for classifying respiratory viruses like RSV, influenza, and COVID-19 in English coded healt…
Coded health records can now identify RSV, flu, and COVID-19 outbreaks without lab tests, helping public health agencies track disease trend…
medRxiv Apr 18, 2026
Meta-analysis finds RSV outcomes peak in early infancy in low- and middle-income countries
Pediatrics Meta-analysis
Meta-analysis finds RSV outcomes peak in early infancy in low- and middle-income countries A New Map Reveals When RSV Hits Young Children Hardest
A systematic review and meta-analysis of 160 datasets from low- and middle-income countries found the peak age for severe RSV outcomes in ch…
A massive new analysis pinpoints the exact infant ages when RSV is most dangerous, providing a crucial blueprint for saving young lives.
Apr 12, 2026
ARTIC-based amplicon sequencing assay evaluated for respiratory syncytial virus detection accuracy and lineage identification
Infectious Disease
ARTIC-based amplicon sequencing assay evaluated for respiratory syncytial virus detection accuracy and lineage identification A New Genetic Tool Could Predict the Next RSV Wave Before It Starts
This evaluation of an assay analyzed 214 deidentified remnant clinical specimens from the Georgia Public Health Laboratory.
This new testing method gives health officials a powerful early warning system to track dangerous RSV strains as they evolve.
medRxiv Apr 12, 2026
US adult vaccination coverage for influenza, COVID-19, and RSV reported in observational data
Infectious Disease
US adult vaccination coverage for influenza, COVID-19, and RSV reported in observational data How many eligible adults are getting their flu, COVID, and RSV shots?
An observational report describes vaccination coverage among eligible US adults for influenza, COVID-19, and RSV vaccines.
A new report shows how many eligible adults across the United States received flu, COVID-19, and RSV vaccines before winter.
CDC Apr 5, 2026
RSV disease severity compared to COVID-19 and influenza in hospitalized older adults
Infectious Disease
RSV disease severity compared to COVID-19 and influenza in hospitalized older adults Study compares RSV severity to COVID-19 and flu in hospitalized older adults
An observational report from the IVY Network across 20 U.S.
A new report compares how serious respiratory syncytial virus is for hospitalized older adults against hospital stays for COVID-19 and the f…
CDC Apr 5, 2026
Human metapneumovirus and respiratory syncytial virus co-circulation described in US
Infectious Disease
Human metapneumovirus and respiratory syncytial virus co-circulation described in US Two common respiratory viruses are circulating together in the US
A non-peer-reviewed report described co-circulation of human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) in the United Stat…
Two common respiratory viruses are circulating together in the US, creating a pattern that could lead to more people getting sick this seaso…
CDC Apr 5, 2026
Report examines vaccination coverage for influenza, RSV, and COVID-19 in US nursing home residents
Infectious Disease
Report examines vaccination coverage for influenza, RSV, and COVID-19 in US nursing home residents Report examines vaccination rates for flu, RSV, and COVID-19 in U.S. nursing homes
A report describes vaccination coverage for influenza, respiratory syncytial virus, and COVID-19 among nursing home residents in the United …
A new report tracks flu, RSV, and COVID-19 vaccine coverage in U.S. nursing homes to see how many residents are getting these important prot…
CDC Apr 5, 2026
Symptom clusters from participatory surveillance data align with specific respiratory pathogens in Dutch and Italian cohorts
Infectious Disease Cohort
Symptom clusters from participatory surveillance data align with specific respiratory pathogens in Dutch and Italian cohorts Can your cough tell you which virus you have? Symptom patterns may hold clues
An observational cohort study of symptomatic participants in Dutch and Italian participatory surveillance platforms used Non-negative Matrix…
Certain cough and cold symptom patterns consistently point to specific viruses like SARS-CoV-2 or the flu across different European countrie…
medRxiv Apr 4, 2026

Research across Human Metapneumovirus Infection

Related studies from across the Human Metapneumovirus Infection family.

Hospitalized children with HMPV infection had 28.0% severe CAP rates and higher risks of wheezing and co-infection
Emergency Medicine Cohort
Hospitalized children with HMPV infection had 28.0% severe CAP rates and higher risks of wheezing and co-infection Premature birth and wheezing raise severe HMPV pneumonia risk
This retrospective cohort study examined 878 hospitalized children with human metapneumovirus (HMPV)-positive community-acquired pneumonia (…
A study of 878 children finds premature birth and wheezing are strong predictors of severe HMPV pneumonia.
Frontiers May 1, 2026
Community cohort study examines symptomatic human metapneumovirus infection incidence
Infectious Disease
Community cohort study examines symptomatic human metapneumovirus infection incidence How common is this respiratory virus in the Pacific Northwest?
A community cohort study in Oregon and Washington assessed the average incidence of symptomatic human metapneumovirus infection.
A study in Oregon and Washington is tracking how often people get sick from human metapneumovirus, a virus that can cause serious breathing …
CDC Apr 5, 2026

Questions about Respiratory Syncytial Virus Infection

Can maternal vaccination protect infants from RSV alongside nirsevimab?

Yes, maternal RSV vaccination and the infant monoclonal antibody nirsevimab work together to protect babies, with nirsevimab providing the primary shield for the first RSV season.

Full answer →
Does nirsevimab prevent RSV in infants born in October 2023?

Yes, nirsevimab prevents RSV in infants born in October 2023, reducing hospitalizations by 70–90% during their first RSV season.

Full answer →
How does RSV disease severity compare to COVID-19 in older adults?

RSV and COVID-19 cause similar severe outcomes in older adults, including ICU admission and death, but RSV may pose higher risk of acute cardiac events.

Full answer →
Where is nirsevimab being rolled out for RSV prevention in infants?

Nirsevimab is being rolled out for infants in New York City and is recommended for high-risk groups including those living with HIV or exposed to HIV.

Full answer →
When do severe RSV outcomes peak in infants in low-income countries?

In low-income countries, severe RSV outcomes like hospitalization and death peak in infants between 2 and 5 months of age.

Full answer →
Can an assay accurately detect respiratory syncytial virus in clinical specimens from Georgia?

Yes, specific assays like whole-genome sequencing developed in Georgia have shown high accuracy for detecting respiratory syncytial virus in clinical specimens.

Full answer →
How does respiratory syncytial virus co-circulate with human metapneumovirus in the United States?

RSV and human metapneumovirus co-circulate in the US, especially during winter and spring, with overlapping seasonal patterns and similar disease spectra.

Full answer →
What is the current vaccination coverage for respiratory syncytial virus among US adults?

As of December 2023, RSV vaccination coverage among US nursing home residents was about 9.8%, with limited data for other adults.

Full answer →
See all 9 questions about Respiratory Syncytial Virus Infection →

All Respiratory Syncytial Virus Infection Articles